Nivolumab, a monoclonal antibody targeting programmed death-1 (PD-1), has revolutionized immunotherapy for various cancers by enhancing T-cell-mediated immune responses. The Nivolumab Biosimilar – Research Grade is a high-quality, cost-effective alternative designed for preclinical and exploratory research. This biosimilar offers consistent performance in assays investigating immune checkpoint pathways, tumor microenvironment, and therapeutic development.
Key Features of Nivolumab Biosimilar
- High Purity and Activity:
- Produced under stringent conditions to ensure high purity and retention of functional activity comparable to the reference product.
- Validated in Research Applications:
- Specifically tailored for use in in-vitro and in-vivo models, including tumor cell line assays and immune profiling studies.
- Cost-Effective Alternative:
- Offers a financially viable option for researchers without compromising on quality, making it suitable for high-throughput experiments.
- Consistency Across Batches:
- Manufactured with robust quality controls, ensuring batch-to-batch consistency for reproducible results.
Applications of Nivolumab Biosimilar – Research Grade
1. Immune Checkpoint Studies
- Explore the role of PD-1/PD-L1 interactions in regulating immune responses.
- Investigate T-cell exhaustion and strategies to reverse it using checkpoint inhibitors (NIH Immune Research).
2. Cancer Research
- Assess the efficacy of immune checkpoint blockade in various cancer models, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (ClinicalTrials.gov).
3. Drug Combination Studies
- Evaluate Nivolumab in combination with other therapies, such as chemotherapy, radiation, or targeted inhibitors, for synergistic effects (FDA Oncology Guidelines).
4. Preclinical Models
- Conduct studies in murine or xenograft models to understand the mechanisms of action, pharmacokinetics, and potential biomarkers for response.
5. Assay Development
- Use in flow cytometry, ELISA, or immunohistochemistry to detect PD-1 expression and modulation in various sample types (PubMed – PD-1 Research).
Specifications
| Feature | Details |
|---|---|
| Target | Programmed death-1 (PD-1) |
| Clone | Monoclonal IgG4, kappa |
| Source | Recombinant expression in mammalian cell systems |
| Applications | In-vitro assays, in-vivo models, and preclinical studies |
| Purity | ≥ 95% as determined by SDS-PAGE and HPLC |
| Endotoxin Level | ≤ 1 EU/mg |
| Storage | -20°C for long-term stability |
| Format | Lyophilized powder or liquid formulation for ease of use |
Mechanism of Action
Nivolumab inhibits PD-1, a receptor expressed on activated T-cells, which binds to its ligands PD-L1 and PD-L2. This interaction dampens the immune response, allowing cancer cells to evade immune detection. By blocking PD-1, Nivolumab restores T-cell activity, promoting tumor cell lysis and immune surveillance (Cancer Research UK).
Experimental Workflow
- Reconstitution:
- Rehydrate lyophilized Nivolumab Biosimilar in sterile water or buffer to the desired concentration.
- In-Vitro Studies:
- Add to cell culture systems to study immune checkpoint inhibition or enhance cytotoxicity assays.
- In-Vivo Models:
- Inject into murine models to evaluate anti-tumor efficacy, pharmacokinetics, or safety profiles.
- Immunoassays:
- Employ in ELISA or flow cytometry to detect PD-1 expression or interaction dynamics.
Advantages of Nivolumab Biosimilar – Research Grade
- Cost-Effective:
- Reduces research costs compared to clinical-grade monoclonal antibodies while maintaining similar activity.
- Flexible Packaging:
- Available in customizable quantities for small-scale experiments or high-throughput studies.
- Validated Consistency:
- Rigorously tested for reproducibility, ensuring reliable results across experiments.
- Ethical Research:
- Suitable for preclinical studies, helping researchers comply with ethical standards before clinical translation.
Relevant Resources and Research
- FDA Immunotherapy Approvals
- NIH PD-1 Research Resources
- ClinicalTrials.gov Studies on PD-1/PD-L1 Blockade
- Cancer Research UK – Immune Checkpoint Inhibitors
- PubMed – Nivolumab Biosimilar Publications
The Nivolumab Biosimilar – Research Grade is a versatile and accessible option for researchers aiming to advance their understanding of immune checkpoint inhibition and its therapeutic applications. Contact your authorized supplier or visit FDA-approved distributors for more information.